Target intelligence / Profile preview

Ribosomal protein L22 pseudogene 1 (RPL22P1)

Target
RPL22P1
Molecular classification
Other (Processed pseudogene)
01

Overview

Ribosomal protein L22 pseudogene 1 (RPL22P1) is a processed pseudogene derived from the functional RPL22 gene. Pseudogenes are DNA sequences similar to known genes but typically non-functional as proteins. RPL22P1 does not encode a functional ribosomal protein, but may be transcribed into RNA. Recent research shows some pseudogene RNAs, including lncRNAs, can be translated or serve as regulatory molecules, but the biological significance of RPL22P1 is unclear; its function, if any, is likely unrelated to classical protein or receptor roles[1][6]. RPL22P1 is not considered a therapeutic target, lacks known drug interactions, mechanism of action, or biomarker status. Its primary relevance is as a genomic element with sequence similarity to RPL22[1].

Other names
RPL22 pseudogene 1ribosomal protein L22P1processed pseudogene of RPL22
02

Biological functions

May function as a long non-coding RNA (lncRNA) or be involved in regulation via RNA mechanisms
03

Disease associations

Other (While some pseudogenes act in cancer and other diseases by regulating gene expression, specific evidence for RPL22P1 in disease is lacking)

Beyond the preview

Go deeper on Ribosomal protein L22 pseudogene 1 (RPL22P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L22 pseudogene 1 (RPL22P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call